作者：E. Louise Thomas PhD, Jimmy D Bell PhD, Aidan Makwana M. Eng, Rexford Newbould PhD, Anil W. Rao PhD, Giulio Gambarota PhD, Paul M. Matthews MD, John D. Beaver PhD, Gary Frost PhD, Bruno Delafont MS, Rajesh G. Mishra MD, ,Evan S. Berk PhD, Susan M. Schwartz PhD。
作者單位：
E. Louise Thomas 博士、Jimmy D Bell博士：英國倫敦帝國理工學(xué)院代謝分子臨床科學(xué)中心；
Aidan Makwana M.工程師、Rexford Newbould博士、Anil W. Rao博士、Giulio Gambarota 博士、Paul M.Matthews 醫(yī)學(xué)博士、John D. Beaver 博士：英國倫敦葛蘭素史克臨床成像中心；
Gary Forst 博士：英國倫敦理工學(xué)院哈默史密斯醫(yī)院營養(yǎng)和營養(yǎng)學(xué)研究小組；
Bruno Delafont 碩士：英國倫敦葛蘭素史克公司生物識別部；
Rajesh G. Mishra 醫(yī)學(xué)博士、Evan S. Berk博士、Susan M. Schwartz博士：美國新澤西葛蘭素史克公司消費者保健部；
【摘自】歐洲臨床營養(yǎng)雜志， 2011年11月第65期1256-1262。
【文獻(xiàn)摘要】
背景和目的：眾多研究發(fā)現(xiàn)，通過低熱量低脂肪飲食，并結(jié)合奧利司他治療，在相同的條件下，比安慰劑能夠減少更多的體重。且這種減肥伴隨著脂肪組織的重新分布。自60mg奧利司他可以作為OTC藥物來使用后，本研究的目的主要是確定在一個運動員數(shù)量極少的社區(qū)中，奧利司他是否可以作為減肥的一個有效選擇。
方法：通過核磁共振成像和核磁波普分析檢測儀器分別測量27個受試者的脂肪組織和脂肪率，且在接下來的3個月通過60mg奧利司他并結(jié)合低熱量低脂的飲食來進(jìn)行治療。
結(jié)果：觀察到受試者的腹內(nèi)脂肪組織減少了10.6%，皮下脂肪減少了11.7%，心包肥胖體積減少了9.8%，肝內(nèi)脂肪減少了43.3%。這些身體脂肪含量分布變化的同時，也伴隨著著血脂水平的改善和血壓、心率的降低。
結(jié)論： 奧利司他60mg可有效降低體重、全身脂肪量、內(nèi)臟脂肪量，并有降低肌間脂肪和肝臟脂肪的趨勢。
【文獻(xiàn)原文】
Pragmatic study of orlistat 60mg on abdominal obesity
Author: E. Louise Thomas PhDa, Aidan Makwana M. Engb, Rexford Newbould PhDb, Anil W. Rao PhDb, Giulio Gambarota PhDb, Gary Frost PhDc, Bruno Delafont MSe, Rajesh G. Mishra MD PhDf, Paul M. Matthews MD DPhilb,d, Evan S. Berk PhDf, Susan M. Schwartz PhDf, Jimmy D Bell PhDa, John D. Beaver PhDb
Author information：
G. Derosa MD PhD：Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy;
A.F.G. Cicero MD PhD; A.D’Angelo BD PhD; E. Fogari MD and P. Maffioli MD : Department of Internal Medicine, Aging and Kidney diseases, “G. Descovich” Atherosclerosis study Center, University of Bologna, Bologna, Italy.
Quote From: European Journal of Clinical Nutrition 65, 1256-1262(November 2011)
【ABSTRACT】
Background and Aims: It is well established combining a reduced calorie, low fat diet with the lipase inhibitor orlistat, results in significantly greater weight loss than placebo plus diet. This weight loss is accompanied by changes in adipose tissue (AT) distribution. Since 60mg orlistat is now available as an over-the-counter medication, the primary objective of this study was to determine whether 60mg orlistat is as effective a weight loss option in a free living community population with minimal professional input.
Methods: Adipose tissue and ectopic lipid content were measured using MRI and 1H MR Spectroscopy (MRS), respectively, in 27 subjects following 3 months treatment with orlistat 60mg and a reduced calorie, low-fat diet.
Results: Significant reductions in intra-abdominal AT (-10.6%, p=0.023) subcutaneous (-11.7% p<0.0001) and pericardial fat (-9.8%, p=0.034) volumes and intra-hepatocellular lipids (IHCL) (-43.3%, p=0.0003) were observed. These changes in body fat content and distribution were accompanied by improvements in plasma lipids and decreases in blood pressure and heart rate.
Conclusion: These findings suggest that over-the-counter 60 mg orlistat, in combination with the type of advice a subject could expect to be given when obtaining 60 mg orlistat in a community setting does indeed result in potentially clinically beneficial changes in body composition and risk factors for metabolic diseases.